[1] Shin H J, Hwang K A, Choi K C. Antitumor effect of various phytochemicals on diverse types of thyroid cancers[J]. Nutrients,2019,11(1):1-11.
[2] 施秉银. 《美国甲状腺结节和分化性甲状腺癌的诊断治疗指南》解读(Ⅱ)[J]. 中华内分泌代谢杂志, 2006, 22 (3):306-308.
[3] Hamilton S N, Tran E, Berthelet E, et al. The role of external beam radiation therapy in well-differentiated thyroid cancer[J]. Expert Rev Anticancer Ther,2017,17(10):905-910.
[4] Sheline G E, Galante M, Lindsay S. Radiation therapy in the control of persistent thyroid cancer[J]. Am J Roentgenol Radium Ther Nucl Med,1966,97(4):923-930.
[5] Chow S M, Law S C, Mendenhall W M, et al. Papillary thyroid carcinoma: prognostic factors and the role of radioiodine and external radiotherapy [J]. Int J Radiat Oncol Biol Phys,2002,52(3):784-795.
[6] Biermann M, Pixberg M, Riemann B, et al. Clinical outcomes of adjuvant external-beam radiotherapy for differentiated thyroid cancer-results after 874 patient-years of follow-up in the MSDS-trial [J]. Nuklearmedizin, 2009, 48(3):89-98, N15.
[7] Haugen B R, Alexander E K, Bible K C, et al. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer[J]. Thyroid,2016,26(1):1-133.
[8] Kiess A P, Agrawal N, Brierley J D, et al. External-beam radiotherapy for differentiated thyroid cancer locoregional control:a statement of the American head and neck society[J]. Head Neck,2016,38(4):493-498.
[9] Kim Y S, Choi J H, Kim K S, et al. The role of adjuvant external beam radiation therapy for papillary thyroid carcinoma invading the trachea[J]. Radiat Oncol J, 2017, 35(2): 112-120
[10] Rosenbluth B D, Serrano V, Happersett L, et al. Intensity-modulated radiation therapy for the treatment of nonanaplastic thyroid cancer[J]. Int J Radiat Oncol Biol Phys,2005,63(5):1419-1426.
[11] 殷德涛,刘晨光.甲状腺癌的放射治疗[J]. 中国实用外科杂志,2019,39(3):206-208.
[12] 张九成,任庆荣,廖玲霞,等. 调强放疗甲状腺癌术后残留的疗效分析[J]. 实用癌症杂志,2014(6):648-650.
[13] 陈焕杰,许 洁,李存琪,等. 甲状腺癌外放射治疗研究进展[J]. 中华普通外科学文献(电子版), 2019, 13(1): 72-75.
[14] 高军茂. 甲状腺癌的放射治疗[J]. 中国医学文摘-耳鼻咽喉科学, 2012,27(3):143-146.
[15] Brierley J, Sherman E. The role of external beam radiation and targeted therapy in thyroid cancer[J]. Semin Radiat Oncol,2012,22(3):254-262.
[16] Romesser P B, Sherman E J, Shaha A R, et al. External beam radiotherapy with or without concurrent chemotherapy in advanced or recurrent non-anaplastic non-medullary thyroid cancer[J]. J Surg Oncol, 2014, 110 (4): 375-382.
[17] Megwalu U C, Orloff L A, Ma Y. Adjuvant external beam radiotherapy for locally invasive papillary thyroid cancer[J]. Head Neck,2019,41(6):1719-1724.
[18] 白 杨,李 杰,张 博,等. 晚期分化型甲状腺癌的规范治疗效果观察[J]. 健康大视野,2019(21):192.
[19] So K, Smith R E, Davis S R. Radiotherapy in well-differentiated thyroid cancer: is it underutilized?[J]. ANZ J Surg, 2016, 86(9):696-700.
[20] Martinez S R, Beal S H, Chen A, et al. Adjuvant external beam radiation for medullary thyroid carcinoma[J]. J Surg Oncol,2010,102(2):175-178.
[21] Wells S J, Asa S L, Dralle H, et al. Revised American thyroid association guidelines for the management of medullary thyroid carcinoma[J]. Thyroid,2015,25(6):567-610.
[22] Call J A, Caudill J S, Mciver B, et al. A role for radiotherapy in the management of advanced medullary thyroid carcinoma: the mayo clinic experience[J]. Rare Tumors,2013,5(3):e37.
[23] Schwartz D L, Rana V, Shaw S, et al. Postoperative radiotherapy for advanced medullary thyroid cancer--local disease control in the modern era[J]. Head Neck,2008,30(7):883-888.
[24] Yang J, Barletta J A. Anaplastic thyroid carcinoma[J]. Semin Diagn Pathol, 2020, 37(5): 248- 256.
[25] He X, Li D, Hu C, et al. Outcome after intensity modulated radiotherapy for anaplastic thyroid carcinoma[J]. BMC Cancer,2014,14:235.
[26] Wang Y, Tsang R, Asa S, et al. Clinical outcome of anaplastic thyroid carcinoma treated with radiotherapy of once- and twice-daily fractionation regimens[J]. Cancer,2006,107(8):1786-1792.
[27] Haddad R I, Lydiatt W M, Ball D W, et al. Anaplastic thyroid carcinoma, Version 2.2015[J]. J Natl Compr Canc Netw, 2015,13(9):1140-1150.
[28] Cortes-Mateus K S, Holub K, Racca F, et al. Concurrent palliative external radiotherapy with sorafenib or doxorubicin for bulky differentiated thyroid carcinoma: a case report[J]. Oncol Lett,2018,16(3):4085-4089.
[29] Terezakis S A, Lee K S, Ghossein R A, et al. Role of external beam radiotherapy in patients with advanced or recurrent nonanaplastic thyroid cancer: Memorial sloan-kettering cancer center experience[J]. Int J Radiat Oncol Biol Phys,2009,73(3):795-801.
[30] Schuck A, Biermann M, Pixberg M K, et al. Acute toxicity of adjuvant radiotherapy in locally advanced differentiated thyroid carcinoma. First results of the multicenter study differentiated thyroid carcinoma (MSDS) [J]. Strahlenther Onkol,2003,179(12):832-839.
[31] Gal T J, Streeter M, Burris J, et al. Quality of life impact of external beam radiotherapy for advanced thyroid carcinoma [J]. Thyroid,2013,23(1):64-69.
[32] Carrillo J F, Flores J M, Espinoza G, et al. Treatment of unresectable differentiated thyroid carcinoma with upfront external radiotherapy and salvage surgery: a STROBE-compliant retrospective cohort study [J]. Front Oncol, 2020, 10:572958.